Press Releases

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced the initiation of dosing in the Phase 2 FORWARD-53 clinical trial, which is evaluating WVE-N531 as a treatment for boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 53 skipping. FORWARD-53 is designed to assess functional dystrophin protein at 24 and 48 weeks with every other week dosing of W

Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced its pivotal STRIDE study (NCT04535609) of mavodelpar in adult patients with primary mitochondrial myopathies (PMM) did not meet its primary efficacy or secondary efficacy endpoint. The primary efficacy endpoint of the trial was the change from baseline in the distance walked during the 12-minut

Alkermes plc (Nasdaq: ALKS) today announced that it has entered into a definitive agreement to sell its development and manufacturing facility in Athlone, Ireland to Novo Nordisk, a leading global healthcare company. Under the terms of the agreement, upon the closing of the transaction, Alkermes will be entitled to a one-time cash payment of $92.5 million for the facility and related assets, subject to customary adjustments in accordance with the agreement. The transaction is expected to clos

ProBioGen announced today that the Japan Patent Office (JPO) issued the first patent for the company’s DirectedLuck® technology. The powerful gene delivery system is based on a highly active transposase fusion variant that enables epigenetic targeting and a carefully designed transposon. This cutting-edge technology provides bulk pools that not only achieve titers of up to 13 g/L for different antibody formats but also exhibit exceptional expression stability over more tha

Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today it has submitted a Clinical Trial Application to Health Canada to obtain permission to proceed with a Phase II trial for LSALT peptide, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and live

Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced the completion of enrollment in its RZ402 Phase 2 study in diabetic macular edema (“DME”). RZ402 is a selective and potent plasma kallikrein inhibitor (“PKI”) being developed as a potential oral therapy for the chronic treatment of DME. The study is a multi-center, randomized

SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, previously announced that MitoCareX Bio Ltd. ("MitoCare X Bio"), its joint venture with Dr. Alon Silberman, that focuses on the discovery and development of drugs for cancer treatment, achieved positive results with the development of its laboratory ca

Pharmaceutical Manufacturing and Packaging Congress (PHARMAP) is an annual networking event, which has a closed-door format: there are no marketing presentations and only decision-makers, technical, supply chain and procurement specialists of key companies are registered for participation. Speakers from Bayer, F. Hoffmann-La Roche, Sandoz, Takeda, Janssen (Johnson & Johnson), Teva Pharmaceuticals and other pharma leaders join the Congress annually to share experiences and collaborate with

ADC Therapeutics SA (NYSE: ADCT) today announced initial results from an investigator-initiated Phase 2 clinical trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with rituximab demonstrated a high response rate in patients with relapsed or refractory (r/r) follicular lymphoma (FL). The data from the single-institution study conducted at the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine were reported during an oral present

C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced that it has entered into an exclusive license and collaboration agreement with Merck (known as MSD outside of the U.S. and Canada) to develop degrader-antibody conjugates (DACs), an emerging modality designed to selectively target and neutr